Ranking Profile - Kalvista Pharmaceuticals Inc

Introduction

Kalvista Pharmaceuticals Inc (Kalvista), formerly Carbylan Therapeutics Inc, is a Biotech company. It focusses on the discovery, development, and commercialization of small molecule protease inhibitors. Its products include KVD824 and KVD001, a plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company's product candidates are inhibitors of plasma kallikrein, which is being developed for hereditary angioedema (HAE) and diabetic macular edema (DME) indications. Kalvista is also progressing additional oral candidates towards regulatory preclinical studies. The company has its operations in the US and the UK. Kalvista is headquartered in Cambridge, Massachusetts, the US.